GoKawiilResearchers detail TRI-611, a brain-penetrant ALK degrader that boosts TKI efficacy
Preclinical data show TRI-611 forms a ternary complex with ALK kinase and CRBN/DDB1, promoting degradation of ALK protein including the EML4-ALK fusion. Combined with TKIs like alectinib and lorlatinib, TRI-611 enhanced tumor suppression in NCI-H3122 xenograft mice without significant body weight loss, indicating a tolerable combination therapy approach.